These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Substantial disease exacerbation in a patient with relapsing-remitting multiple sclerosis after withdrawal from siponimod.
    Author: Litwin T, Smoliński Ł, Członkowka A.
    Journal: Neurol Neurochir Pol; 2018; 52(1):98-101. PubMed ID: 29110882.
    Abstract:
    Among patients with multiple sclerosis, discontinuing highly effective disease-modifying treatments can potentially lead to severe disease recurrence, especially cessation of natalizumab and fingolimod. Similar to fingolimod, siponimod is a sphingosine-1-phosphate receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph nodes. In the present case report, we describe a patient with MS who experienced substantial disease exacerbation after withdrawal from siponimod.
    [Abstract] [Full Text] [Related] [New Search]